News
Short-term stock returns are largely driven by the perception of near-term earnings per share. Read more here.
Bailard Inc. drastically reduced its stake in Regeneron Pharmaceuticals, offloading 69.9% of its shares in the first quarter.
If you're looking for stocks that can make dramatic movements in a short time frame, the biotechnology space has what you ...
Despite some near-term revenue growth, HRTX's future is uncertain. Click here to find out why HRTX stock is a Hold.
1d
Zacks Investment Research on MSNHere's Why Repligen (RGEN) is a Strong Growth StockTaking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...
Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
5d
Investor's Business Daily on MSNStocks Showing Rising Market Leadership: Ligand Pharmaceuticals Earns 84 RS RatingLigand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84.
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results